Citations

Showing 10 of 108083 citations.

A peptoid interleukin‐15 receptor antagonist suppresses inflammation and arthritis in mice
Cho, Kwang Bog , Shukla, Satya Prakash , Kannan, Maheshkumar, Amina, Sundus Jabeen, Chen, Yanping , Molligan, Jeremiah F., Mohan, Chandra , Udugamasooriya, D. Gomika , Guo, Bin , Udugamasooriya, D Gomika , Guo, Bin , Zhang, Haowen , Zhou, Shuang Ying , Chen, Yanping, Taneja, Veena

Mayo Clinic

Clinical & Translational Immunology | November 24, 2022 | Volume: 11 | Issue: 11 | Pages: No page available

10.1002/cti2.1432 | PMID 36439637 Get It

AbstractObjectiveTo discover a novel peptoid antagonist that targets the interleukin‐15 (IL‐15) receptor and to evaluate its therapeutic efficacy in the treatment of inflammation and arthritis.MethodsA new compound (IFRA3, interleukin‐15 receptor antagonist 3) was discovered using a unique on‐bead two‐colour combinatorial cell screening of a peptoid library. The interaction of IFRA3 with IL‐15 receptor was assessed by in vitro pull‐down and thermal shift assays. The efficacy of IFRA3 in treating inflammation and arthritis was evaluated in mouse models.ResultsIFRA3Q1 (a tetrameric derivative of IFRA3) inhibited the activity of IL‐15 and suppressed CTLL‐2 cell proliferation (which depends on IL‐15 activity). IFRA3Q1 exhibited strong in vivo anti‐inflammatory activity in carrageenan‐induced inflammation in mice. Furthermore, IFRA3Q1 inhibited collagen‐induced arthritis in DBA/1J mice.ConclusionBy binding to and inhibiting the function of IL‐15 receptor, IFRA3Q1 exhibited significant anti‐arthritis activity. Our findings suggest that IFRA3Q1 represents a new paradigm for arthritis therapy by targeting IL‐15 signalling.
Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee
Buxbaum, Joel N. , Fändrich, Marcus , Saraiva, Maria João , Sekijima, Yoshiki , Westermark, Per , Dispenzieri, Angela , Eisenberg, David S , Merlini, Giampaolo

Mayo Clinic

Amyloid | November 24, 2022 | Volume: 29 | Issue: 4 | Pages: 213-219

10.1080/13506129.2022.2147636 | PMID 36420821 Get It

Optical genome mapping in acute myeloid leukemia: a multicenter evaluation
Levy, Brynn , Akkari, Yassmine, Chartrand, Scott, LaBarge, Brandon, Claxton, David F. , Lennon, Patrick A. , Cujar, Claudia , Kolhe, Ravindra , Kroeger, Kate, Sahajpal, Nikhil , Sathanoori, Malini, Vlad, George , Zhang, Lijun , Fang, Min , Kanagal‐Shamanna, Rashmi , Claxton, David F , Cujar, Claudia , Kolhe, Ravindra , Pitel, Beth A , Zhang, Lijun , Kanagal-Shamanna, Rashmi , Broach, James R , Baughn, Linda B. , Pitel, Beth A.

Mayo Clinic

Blood Advances | November 24, 2022 | Volume: 7 | Issue: 7 | Pages: 1297-1307

10.1182/bloodadvances.2022007583 | PMID 36417763 Get It

Abstract Detection of hallmark genomic aberrations in acute myeloid leukemia (AML) is essential for diagnostic subtyping, prognosis, and patient management. However, cytogenetic/cytogenomic techniques used to identify those aberrations, such as karyotyping, fluorescence in situ hybridization (FISH), or chromosomal microarray analysis (CMA), are limited by the need for skilled personnel as well as significant time, cost, and labor. Optical genome mapping (OGM) provides a single, cost-effective assay with a significantly higher resolution than karyotyping and with a comprehensive genome-wide analysis comparable with CMA and the added unique ability to detect balanced structural variants (SVs). Here, we report in a real-world setting the performance of OGM in a cohort of 100 AML cases that were previously characterized by karyotype alone or karyotype and FISH or CMA. OGM identified all clinically relevant SVs and copy number variants (CNVs) reported by these standard cytogenetic methods when representative clones were present in >5% allelic fraction. Importantly, OGM identified clinically relevant information in 13% of cases that had been missed by the routine methods. Three cases reported with normal karyotypes were shown to have cryptic translocations involving gene fusions. In 4% of cases, OGM findings would have altered recommended clinical management, and in an additional 8% of cases, OGM would have rendered the cases potentially eligible for clinical trials. The results from this multi-institutional study indicate that OGM effectively recovers clinically relevant SVs and CNVs found by standard-of-care methods and reveals additional SVs that are not reported. Furthermore, OGM minimizes the need for labor-intensive multiple cytogenetic tests while concomitantly maximizing diagnostic detection through a standardized workflow.
Identification of motifs and mechanisms for lipid droplet targeting of the lipolytic inhibitors G0S2 and HIG2
Campbell, Latoya E., Anderson, Aaron , Chen, Yongbin , Johnson, S. M. , McMahon, Cailin E., Liu, Jun , Anderson, Aaron M, Johnson, Scott M, Liu, Jun

Mayo Clinic

Journal of Cell Science | November 24, 2022 | Volume: 135 | Issue: 24 | Pages: No page available

10.1242/jcs.260236 | PMID 36420951 Get It

ABSTRACT G0S2 and HIG2 are two selective inhibitors of ATGL (also known as PNPLA2), the key enzyme for intracellular lipolysis. Whereas G0S2 regulates triglyceride (TG) mobilization in adipocytes and hepatocytes, HIG2 functions to enhance intracellular TG accumulation under hypoxic conditions. A homologous hydrophobic domain (HD) is shared by G0S2 and HIG2 (also known as HILPDA) for binding to ATGL. However, the determinants of their lipid droplet (LD) localization are unknown. Here, we study how G0S2 and HIG2 are targeted to LDs, and identify both ATGL-independent and -dependent mechanisms. Structural prediction and studies in cells reveal that ATGL-independent localization of G0S2 to both the endoplasmic reticulum (ER) and LDs is mediated by a hairpin structure consisting of two hydrophobic sequences. Positively charged residues in the hinge region play a crucial role in sorting G0S2, which initially localizes to ER, to LDs. Interestingly, the role of these positive charges becomes dispensable when ATGL is co-expressed. In comparison, HIG2, which lacks a similar hairpin structure, is dependent on ATGL for its full LD targeting. Thus, our studies identify specific structural features and mechanisms for mediating accumulation of these two ATGL inhibitors on LDs.
Could a Moth's Stealth Technology Make Our World a Little Quieter?
Carmichael, Stephen W.

Mayo Clinic

Microscopy Today | November 24, 2022 | Volume: 30 | Issue: 6 | Pages: 8-9

10.1017/s1551929522001249 Get It

Quantifying factors that affect polygenic risk score performance across diverse ancestries and age groups for body mass index
Hui, Daniel J. , Xiao, Brenda , Irvin, Marguerite R. , Kullo, Iftikhar, Limdi, Nita A. , Liu, Cong , Namjou, Bahram , Puckelwartz, Megan J. , Schaid, Daniel J. , Tiwari, Hemant K., Wei, Wei‐Qi, Ritchie, Marylyn D. , Liu, Cong , Puckelwartz, Megan J , Dikilitas, Ozan , Freimuth, Robert R. , Jarvik, Gail P. , Kottyan, Leah C. , Luo, Yuan , Verma, Shefali S. , Kim, Dokyoon

Mayo Clinic

Biocomputing 2023 | November 24, 2022 | Volume: No volume available | Issue: No issue available | Pages: 437-448

10.1142/9789811270611_0040 Get It

Central Haemodynamic Abnormalities and Outcome in Patients with Unexplained Dyspnoea
Omote, Kazunori , Sorimachi, Hidemi, Popović, Dejana , Reddy, Yogesh N.V. , Nishimura, Rick , Verbrugge, Frederik H. , Omar, Massar , Obokata, Masaru , Borlaug, Barry A.

Mayo Clinic

European Journal of Heart Failure | November 24, 2022 | Volume: 25 | Issue: 2 | Pages: 185-196

10.1002/ejhf.2747 | PMID 36420788 Get It

Abstract Aims Little data are available regarding prognostic implications of invasive exercise testing in heart failure with preserved ejection fraction (HFpEF). The present study aimed to investigate whether rest and exercise central haemodynamic abnormalities are associated with adverse clinical outcomes in patients with dyspnea. Methods and results Patients with exertional dyspnoea and ejection fraction ≥50% (n = 764) underwent invasive exercise testing and follow-up for heart failure hospitalization or death. There were 117 patients with events over a median follow-up of 2.7 (interquartile range 0.5–4.6) years. Among patients with normal resting pulmonary artery wedge pressure (PAWP) (<15 mmHg, n = 380 [50%]), increased exercise PAWP (≥25 mmHg) was present in 187 (24% of cohort) and was associated with 2.4-fold higher risk of events compared to those with normal exercise PAWP (<25 mmHg, n = 193 [25%]) (hazard ratio [HR] 2.44; 95% confidence interval [CI] 1.11–5.36; p = 0.03), while patients with elevated resting PAWP (≥15 mmHg, n = 384 [50%]) displayed even higher risk compared to HFpEF with normal resting PAWP (HR 2.24; 95% CI 1.38–3.65; p = 0.001). Similar findings were observed for rest/exercise right atrial pressure, and rest/exercise pulmonary artery pressures. Higher peak oxygen consumption was associated with decreased risk of events, and this relationship was solely explained by exercise cardiac output. In a multivariable-adjusted Cox model, each 1 standard deviation (SD) increase in exercise PAWP was associated with a 41% greater hazard of events (HR 1.41; 95% CI 1.13–1.76; p = 0.002), while each 1 SD decrease in exercise cardiac output was associated with a 37% increased risk (HR 0.63; 95% CI 0.47–0.83; p = 0.001). Conclusions Haemodynamic abnormalities currently used for diagnosis of HFpEF are associated with increased risk for adverse events. Treatments that reduce central pressures while improving cardiac output reserve may offer greatest benefit to improve outcomes in HFpEF.
Mitochondria as disease-relevant organelles in rheumatoid arthritis
Weyand, Cornelia M. , Huang, Tao , Hu, Zhao‐Lan , Goronzy, Jörg J. , Wu, Bowen, Hu, Zhaolan, Goronzy, Jorg , Wu, Bowen

Mayo Clinic

Clinical and Experimental Immunology | November 24, 2022 | Volume: 211 | Issue: 3 | Pages: 208-223

10.1093/cei/uxac107 | PMID 36420636 Get It

SummaryMitochondria are the controllers of cell metabolism and are recognized as decision makers in cell death pathways, organizers of cytoplasmic signaling networks, managers of cellular stress responses, and regulators of nuclear gene expression. Cells of the immune system are particularly dependent on mitochondrial resources, as they must swiftly respond to danger signals with activation, trafficking, migration, and generation of daughter cells. Analogously, faulty immune responses that lead to autoimmunity and tissue inflammation rely on mitochondria to supply energy, cell building blocks and metabolic intermediates. Emerging data endorse the concept that mitochondrial fitness, and the lack of it, is of particular relevance in the autoimmune disease rheumatoid arthritis (RA) where deviations of bioenergetic and biosynthetic flux affect T cells during early and late stages of disease. During early stages of RA, mitochondrial deficiency allows naïve RA T cells to lose self-tolerance, biasing fundamental choices of the immune system toward immune-mediated tissue damage and away from host protection. During late stages of RA, mitochondrial abnormalities shape the response patterns of RA effector T cells engaged in the inflammatory lesions, enabling chronicity of tissue damage and tissue remodeling. In the inflamed joint, autoreactive T cells partner with metabolically reprogrammed tissue macrophages that specialize in antigen-presentation and survive by adapting to the glucose-deplete tissue microenvironment. Here, we summarize recent data on dysfunctional mitochondria and mitochondria-derived signals relevant in the RA disease process that offer novel opportunities to deter autoimmune tissue inflammation by metabolic interference.
Alpha-T-catenin is expressed in peripheral nerves as a constituent of Schwann cell adherens junctions
Weng, Anthea , Rabin, Erik E. , Flozak, Annette S. , Aillon, Raul Piseaux, Gottardi, Cara J. , Chiarella, Sergio E , Gottardi, Cara J , Chiarella, Sergio E.

Mayo Clinic

Biology Open | November 24, 2022 | Volume: 11 | Issue: 12 | Pages: No page available

10.1242/bio.059634 | PMID 36420826 Get It

ABSTRACT The adherens junction component, alpha-T-catenin (αTcat) is an established contributor to cardiomyocyte junction structure and function, but recent genomic studies link CTNNA3 polymorphisms to diseases with no clear cardiac underpinning, including asthma, autism and multiple sclerosis, suggesting causal contributions from a different cell-type. We show Ctnna3 mRNA is highly expressed in peripheral nerves (e.g. vagus and sciatic), where αTcat protein enriches at paranodes and myelin incisure adherens junctions of Schwann cells. We validate αTcat immunodetection specificity using a new Ctnna3-knock-out fluorescence reporter mouse line yet find no obvious Schwann cell loss-of-function morphology at the light microscopic level. CTNNA3/Ctnna3 mRNA is also abundantly detected in oligodendrocytes of the central nervous system via public databases, supporting a general role for αTcat in these unique cell–cell junctions. These data suggest that the wide range of diseases linked to CTNNA3 may be through its role in maintaining neuroglial functions of central and peripheral nervous systems. This article has a corresponding First Person interview with the co-first authors of the paper.